Moon Shot helps corner aggressive-variant prostate cancer
Prostate cancer is the most common cancer diagnosed in American men, and the second leading cause of cancer death in men. While hormone-based therapies are effective for many men, there remain an estimated 20% of patients who will not benefit and have significantly worse outcomes.
These patients have a subtype of prostate cancer known as aggressive variant prostate cancer (AVPC), which does not respond to therapies that block...
Blocking protein reduces fibrosis, thwarts ovarian and pancreatic cancer
Using an antibody to plug a protein secreted by fibrous tissues in tumors stifles ovarian and pancreatic cancer in mouse models by reducing...
New approach enhances PD-L1 detection to aid in immunotherapy selection
Just as a driver’s night vision improves by simply cleaning the headlights, scientists at The University of Texas MD Anderson Cancer Center...
International consortium publishes recommendations for neoadjuvant melanoma trials
An international consortium, led in part by clinicians and researchers from The University of Texas MD Anderson Cancer Center, has published a series of best-practice recommendations for conducting clinical trials for neoadjuvant, or pre-surgical, therapies in patients with locally advanced melanoma.
The report, published in Lancet Oncology, provides recommendations for clinical trial design, including patient inclusion criteria...
